Table 3.

Multivariate analysis of cfPWV and AIx@75 between APS, DM and HC.

	Β coefficient	95% CI	p-value
cfPWV
Model 1a
APS vs HC	−0.142	−0.514, 0.230	0.454
APS vs DM	−0.863	−1.223, −0.500	<0.001
Model 2b
APS vs HC	−0.142	−0.498, 0.214	0.434
APS vs DM	−0.909	−1.263, −0.555	<0.001
Model 3c
APS vs HC	−0.133	−0.489, 0.223	0.464
APS vs DM	−0.904	−1.254, −0.554	<0.001
AΙx@75
Model 1d
APS vs HC	4.525	1.372, 7.677	0.005
APS vs DM	2.046	−1.040, 5.132	0.193
Model 2e
APS vs HC	4.164	1.259, 7.069	0.005
APS vs DM	1.750	−1.165, 4.665	0.238
Model 3f
APS vs HC	4.124	1.222, 7.027	0.006
APS vs DM	2.017	−0.857, 4.891	0.168

Values in bold are statistically significant.

cfPWV: carotid-femoral pulse wave velocity; AIx@75: augmentation index normalized for heart rate of 75 bpm; CI: confidence interval; APS: antiphospholipid syndrome; DM: diabetes mellitus; HC: healthy controls; MAP: mean arterial pressure (brachial); LDL: low density lipoprotein; CKD: chronic kidney disease (stages III-IV); BMI: body mass index.

^aAdjusted for age, MAP (brachial), smoking (pack-years), LDL, BMI, anti-hypertensives and statins use, CKD (stages 3–4) and plaque presence.

^bAdjusted for age, MAP (brachial), number of traditional CVRFs, anti-hypertensives and statins use, CKD (stages 3–4) and plaque presence.

^cAdjusted for age, MAP (brachial), number of traditional CVRFs, CKD (stages 3–4) and plaque presence.

^dAdjusted for age, sex, MAP (brachial), smoking (pack-year), LDL levels, BMI, anti-hypertensives, statins and anti-platelets use, exercise, CKD (stages 3–4) and plaque presence.

^eAdjusted for age, sex, MAP (brachial), number of traditional CVRFs, anti-hypertensives and statins use, exercise, CKD (stages 3–4) and plaque presence.

^fAdjusted for age, sex, MAP (brachial), number of traditional CVRFs, exercise, CKD (stages 3–4) and plaque presence.